Infectious Diseases

Following historical budget allocation, Canada enters BIO 2018 with thriving life science industry

June 6, 2018

Following historical budget allocation, Canada enters BIO 2018 with thriving life science industry Contact: Brendan Monahan Rasky Partners, Inc. 413-537-4063 Boston, Ma (June 1st, 2018) –The size and prominence of the Canadian delegation arriving at BIO 2018 – among the largest international delegation – demonstrates the tremendous success that the government’s record setting investment […]

Chintu Patel Named Chief Executive Officer, Adello Biologics, LLC

May 15, 2018

Founding and leading Amneal Pharmaceuticals for 15 years, Mr. Patel and his brother Chirag transformed the company from a small, start-up generic manufacturer into the 5th largest generic pharmaceutical company in the U.S. Under the leadership of Chintu and Chirag Patel, Amneal grew to manufacture hundreds of generic pharmaceutical products in all dosage forms, including […]

Amneal Gains Approval for Erythromycin Tablets USP

March 14, 2018

Amneal Pharmaceuticals has received FDA approval for Erythromycin Tablets USP, 250 mg and 500 mg strengths.  The Amneal product is a therapeutic equivalent for the reference listed drug (RLD) Erythromycin Tablets from Arbor Pharmaceuticals and is the only other immediate release oral tablet available. “Amneal is committed to increasing access to affordable medications,” said Amneal […]

Global BioLife, a Singapore eDevelopment subsidiary, confirms LB2 efficacy against Ebola

March 6, 2018

Singapore – Singapore eDevelopment (SGX: 40V) announces that biomedical subsidiary Global BioLife, Inc. has completed the initial Zaire Ebola research portion for a study of the new anti-viral drug LB2, part of a new universal therapeutic drug platform, Linebacker, which was designed to combat a range of diseases, including neurological, anti-microbial, anti-viral, and oncology. Global BioLife is […]

Amneal Launches Generic for Tamiflu® Oral Suspension

March 1, 2018

Bridgewater, NJ (USA), March 1, 2018 – Amneal Pharmaceuticals has launched oseltamivir phosphate for oral suspension, the company’s AB-rated therapeutic equivalent for Tamiflu®, in a 6 mg/mL strength.  The powder finished dosage form is made in the U.S.A. and packaged in bottles providing 60 mL of usable volume after constitution. Amneal’s oseltamivir phosphate for oral […]